Program
Immunoglobulins, Intravenous
Also written as “NPB-01”, “TAK-881” and “IVIG”.
Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.
Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 203 open or running | phase 4since Apr 12, 2017 | Sep 8, 2005 | May 16, 2028phase 3 · NCT06076642 |
| Grifolsits history only | 172 open or running | phase 4since Oct 24, 2011 | Sep 13, 2005 | Dec 31, 2027phase 3 · NCT07540221 |
| Nihon Pharmaceuticalits history only | 80 open or running | phase 3since Jul 27, 2011 | Dec 11, 2008 | none ahead |
| Octapharmaits history only | 61 open or running | phase 3since Nov 11, 2009 | Nov 11, 2009 | Nov 2026phase 3 · NCT04640142 |
| CSLits history only | 51 open or running | phase 3since Oct 12, 2011 | Oct 12, 2011 | May 6, 2029phase 2 · NCT07048262 |
| Kedrionits history only | 53 open or running | phase 3since Apr 16, 2012 | Apr 16, 2012 | Dec 2026phase 3 · NCT07059000 |
| Japan Blood Products Organizationits history only | 40 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| GC Biopharmaits history only | 31 open or running | phase 3since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Prothya Biosolutions | 30 open or running | phase 4since Aug 29, 2007 | Aug 29, 2007 | none ahead |
| Azidus Brasilits history only | 22 open or running | phase 3since Sep 19, 2023 | Sep 19, 2023 | Sep 2028phase 3 · NCT06150833 |
| Benesisits history only | 20 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| Biopharma Plasmaits history only | 20 open or running | phase 3since Jul 15, 2020 | Jul 15, 2020 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Dobri Kiprovits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Evolve Biologicsits history only | 10 open or running | phase 3since Jul 21, 2017 | Jul 21, 2017 | none ahead |
| GammaCanits history only | 10 open or running | phase 2since Feb 19, 2006 | Feb 19, 2006 | none ahead |
| IMMUNOe Research Centersits history only | 10 open or running | phase 4since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Isaac Melamedits history only | 10 open or running | phase 4since Jul 21, 2014 | Jul 21, 2014 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Prothya Biosolutions only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2007First study: phase 4 study in IgG DeficiencyFirst studyNCT00522821 · 55 enrolled · Netherlands
- May 1, 2009Phase 3 study in CardiomyopathiesNCT00892112 · 50 enrolled · Netherlands
- Oct 31, 2013Phase 3 study in Primary Immunodeficiency DiseasesNCT01985373 · 23 enrolled · Netherlands
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Prothya Biosolutions leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01985373Primary Immunodeficiency Diseases · Netherlands | 3 | Completed | Mar 2015 | 23 |
| NCT00892112Cardiomyopathies · Netherlands | 3 | Completed | Jun 2018 | 50 |
| NCT00522821IgG Deficiency · Netherlands | 4 | Completed | Jul 2014 | 55 |
How it is read
Names in the registry
- “NPB-01”, 7 entries
- “TAK-881”, 6 entries
- “IVIG”, 6 entries
- “Kedrion IVIG 10%”, 4 entries
- “GB-0998”, 4 entries
Codes read as this program: TAK881, GC5107, GB0998.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 24 studies
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 5 studies
- Immunologic Deficiency Syndromes, 4 studies
- Myasthenia Gravis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.